
    
      This was a Phase 2a, two-staged, single-arm, open-label study in sorafenib-na√Øve patients
      with advanced HCC.

      Patients received 5 weekly IV infusions of Pexa-Vec and could have continued to receive IV
      infusions of Pexa-Vec every 3 weeks until progressive disease (PD).
    
  